Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.42 |
| ▸ | GLP1R | P43220 | 7/20 | 0.42 |
| ▸ | GIPR | P48546 | 7/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30473784 | 1.00 | CXCR4 (0.43) | CXCR4APLNRBDKRB2GLP1RGIPR | |
| SCHEMBL30473772 | 0.96 | OPRM1 (0.46) | CXCR4APLNRBDKRB2GLP1RGIPR | |
| SCHEMBL30473780 | 0.96 | OPRM1 (0.46) | CXCR4APLNRBDKRB2GLP1RGIPR | |
| SCHEMBL29358088 | 0.95 | APLNR (0.46) | CXCR4APLNRBDKRB2GLP1RGIPR | |
| SCHEMBL29669221 | 0.91 | CXCR4 (0.49) | CXCR4APLNRGLP1RGIPROPRD1 | |
| SCHEMBL30914237 | 0.90 | OPRM1 (0.47) | APLNRBDKRB2GLP1RGIPROPRD1 | |
| SCHEMBL31399254 | 0.89 | OPRM1 (0.46) | CXCR4APLNRGLP1RGIPROPRD1 | |
| SCHEMBL31042468 | 0.88 | OPRM1 (0.42) | CXCR4APLNRBDKRB2OPRD1OPRM1 | |
| SCHEMBL29554130 | 0.86 | CAPN1 (0.47) | APLNRBDKRB2OPRD1OPRM1CAPN1 | |
| SCHEMBL30307615 | 0.86 | OPRM1 (0.46) | CXCR4BDKRB2OPRD1OPRM1CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116390938-A | Exendin-4 analogues | TXP制药股份有限公司 | 2023-07-04 | — | — | CN | disclosed |